Caricamento...
A Phase II Evaluation of Ixabepilone (IND #59699, NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus: an NRG Oncology/Gynecologic Oncology Group Study
BACKGROUND: The combination of gemcitabine and docetaxel is standard first-line therapy for recurrent or metastatic uterine leiomyosarcoma. There is no standard second-line therapy. Ixabepilone is a semi-synthetic analog of epothilone B that binds to the same site on beta tubulin as paclitaxel and m...
Salvato in:
| Pubblicato in: | Gynecol Oncol |
|---|---|
| Autori principali: | , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2014
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4497546/ https://ncbi.nlm.nih.gov/pubmed/25091619 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2014.07.101 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|